Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $55.2 million.

  • Prime Medicine's Operating Expenses rose 139.05% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.9 million, marking a year-over-year decrease of 755.08%. This contributed to the annual value of $205.4 million for FY2024, which is 32.13% up from last year.
  • Per Prime Medicine's latest filing, its Operating Expenses stood at $55.2 million for Q3 2025, which was up 139.05% from $54.5 million recorded in Q2 2025.
  • Prime Medicine's Operating Expenses' 5-year high stood at $68.0 million during Q4 2023, with a 5-year trough of $10.4 million in Q3 2021.
  • Its 5-year average for Operating Expenses is $44.8 million, with a median of $48.9 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Prime Medicine's Operating Expenses was 20358.68% (2022), while the steepest drop was 3560.49% (2022).
  • Quarter analysis of 5 years shows Prime Medicine's Operating Expenses stood at $60.1 million in 2021, then plummeted by 35.6% to $38.7 million in 2022, then soared by 75.89% to $68.0 million in 2023, then tumbled by 31.8% to $46.4 million in 2024, then rose by 18.95% to $55.2 million in 2025.
  • Its last three reported values are $55.2 million in Q3 2025, $54.5 million for Q2 2025, and $53.8 million during Q1 2025.